Blocking TNF-α/TNFR2 Signaling in Colorectal Cancer
Author Information
Author(s): Guo Yixian, Xie Feng, Liu Xu, Ke Shouyu, Chen Jieqiong, Zhao Yi, Li Ning, Wang Zeyu, Yi Gang, Shen Yanying, Li Dan, Zhu Chunchao, Zhang Zizhen, Zhao Gang, Lu Hong, Li Bin, Zhao Wenyi, Lu Hua
Primary Institution: Shanghai Jiao Tong University School of Medicine
Hypothesis
Can blocking TNF-α/TNFR2 signaling improve anti-PD1 immunotherapy efficacy in colorectal cancer by reducing CCR8+ T regulatory cells?
Conclusion
Blocking TNF-α/TNFR2 signaling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy.
Supporting Evidence
- High levels of TNFR2+CCR8+ Tregs are associated with poor prognosis in CRC patients.
- TNF-α upregulates CCR8 expression in Tregs via the TNFR2/NF-κB pathway.
- Depletion of Tnfr2 reduces CCR8+ Treg infiltration and enhances anti-PD1 therapy efficacy.
Takeaway
This study shows that a specific type of immune cell, when blocked, can help cancer treatments work better.
Methodology
The study used murine models and patient samples to analyze the effects of TNF-α/TNFR2 signaling on T regulatory cells and tumor growth.
Potential Biases
Potential bias in patient selection and sample size.
Limitations
The study primarily focuses on murine models, which may not fully replicate human responses.
Participant Demographics
Patients with colorectal cancer undergoing surgery.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website